Gastroenterology Drug Discovery Unit, Takeda Pharmaceutical Company Limited, Kanagawa, Japan.
Florey Institute of Neuroscience and Mental Health, Parkville, Vic., Australia.
Neurogastroenterol Motil. 2020 Aug;32(8):e13866. doi: 10.1111/nmo.13866. Epub 2020 Apr 26.
Muscarinic receptor 1 positive allosteric modulators (M1PAMs) enhance colonic propulsive contractions and defecation through the facilitation of M1 receptor (M1R)-mediated signaling. We examined M1R expression in the colons of 5 species and compared colonic propulsion and defecation caused by the M1PAM, T440, the 5-HT agonist, prucalopride, and the cholinesterase inhibitor, neostigmine, in rats and dogs.
M1R expression was profiled by immunostaining and in situ hybridization. In vivo studies utilized male SD rats and beagle dogs. Colonic propulsive contractions were recorded by manometry in anesthetized rats. Gut contractions in dogs were assessed using implanted force transducers in the ileum, proximal, mid, and distal colons.
M1R was localized to neurons of myenteric and submucosal plexuses and the epithelium of the human colon. A similar receptor localization was observed in rat, dog, mouse, and pig. T440 enhanced normal defecation in rats in a dose-dependent manner. Prucalopride also enhanced defecation in rats, but the maximum effect was half that of T440. Neostigmine and T440 were similarly effective in enhancing defecation, but the effective dose of neostigmine was close to its lethal dose. In rats, all 3 compounds induced colonic contractions, but the associated propulsion was strongest with T440. In dogs, intestinal contractions elicited by T440 propagated from ileum to distal colon. Prucalopride and neostigmine also induced intestinal contractions, but these were less well coordinated. No loss of effectiveness of T440 on defecation occurred after 5 days of repeated dosing.
These results suggest that M1PAMs produce highly coordinated propagating contraction by actions on the enteric nervous system of the colon. The localization of M1R to enteric neurons in both animals and humans suggests that the M1PAM effects would be translatable to human. M1PAMs provide a potential novel therapeutic option for constipation disorders.
毒蕈碱受体 1 正向变构调节剂(M1PAMs)通过促进 M1 受体(M1R)介导的信号转导,增强结肠推进性收缩和排便。我们检查了 5 种物种结肠中的 M1R 表达,并比较了 M1PAM、5-HT 激动剂普卡必利、胆碱酯酶抑制剂新斯的明引起的大鼠和犬的结肠推进和排便。
通过免疫染色和原位杂交分析 M1R 表达。体内研究使用雄性 SD 大鼠和比格犬。通过麻醉大鼠的测压法记录结肠推进性收缩。使用植入在回肠、近端、中段和远端结肠中的力传感器评估犬的肠道收缩。
M1R 定位于人结肠的肌间和黏膜下神经丛神经元以及上皮细胞。在大鼠、狗、小鼠和猪中观察到类似的受体定位。T440 以剂量依赖性方式增强大鼠的正常排便。普卡必利也增强了大鼠的排便,但最大效果是 T440 的一半。新斯的明和 T440 同样有效地增强排便,但新斯的明的有效剂量接近其致死剂量。在大鼠中,所有 3 种化合物均引起结肠收缩,但 T440 引起的推进作用最强。在犬中,T440 引起的肠收缩从回肠传播到远端结肠。普卡必利和新斯的明也引起肠道收缩,但这些收缩不太协调。经过 5 天的重复给药后,T440 对排便的有效性没有下降。
这些结果表明,M1PAMs 通过作用于结肠的肠神经系统产生高度协调的传播收缩。M1R 在动物和人类中的肠神经元中的定位表明,M1PAM 的作用将可转化为人类。M1PAMs 为便秘障碍提供了一种潜在的新型治疗选择。